drugset / Trial / NCT00003715

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

NCT00003715

Phase 2 Terminated 425 enrolled AVAX Technologies
RandomizedTreatment

Summary

RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.

Timeline

Start
1998-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Other
Subject interferon alfa-2b Protein / enzyme biologic Intravenous
Background BCG vaccine Vaccine
Background Cyclophosphamide Other / unclassified

Indications